Pre-made Risankizumab benchmark antibody ( Whole mAb, anti-IL23A/IL23 therapeutic antibody, Anti-IL23P19/P19/SGRF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Risankizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States, Canada, and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-486-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Risankizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
INN Name	Risankizumab
Target	IL23
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	AbbVie;Boehringer Ingelheim
Conditions Approved	Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions Active	Crohn's disease;Ulcerative colitis;Atopic dermatitis
Conditions Discontinued	Psoriasis;Ankylosing spondylitis;Asthma
Development Tech	na